Health Canada's Bureau of Biologics and Radiopharmaceuticals hasgranted approval for Chiron to market its Menjugate vaccine to prevent disease caused by the bacteria Neisseria meningitidis serogroup C. In Canada, Merck Frosst will be the exclusive distributor of the vaccine, which was first licensed in the UK last year (Marketletter March 6, 2000). Chiron is also applying for registration throughout the European Union by means of the Mutual Recognition procedure. First-quarter sales of the vaccine fell to $29 million from $60 million a year earlier, on lower shipments to the UK, which had suffered a meningitis outbreak in the same period of 2000.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze